Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13626884 | 0.89 | ATM (0.46) | CTSSCTSKATMITGB3ITGA2B | |
| SCHEMBL2617257 | 0.87 | ATM (0.43) | CTSSCTSKATMITGB3ITGA2B | |
| SCHEMBL2617245 | 0.83 | ATM (0.43) | CTSSCTSKATMITGB3ITGA2B | |
| SCHEMBL2617321 | 0.82 | CTSS (0.56) | CTSSCTSKATMCACNA1BAAK1 | |
| SCHEMBL2617255 | 0.82 | CTSS (0.56) | CTSSCTSKATMCACNA1BAAK1 | |
| SCHEMBL27395092 | 0.82 | MAPT (0.41) | CTSSCTSKCACNA1BAAK1MEN1 | |
| SCHEMBL30243990 | 0.82 | MAPT (0.41) | CTSSCTSKCACNA1BAAK1MEN1 | |
| SCHEMBL2617260 | 0.80 | ATM (0.39) | CTSSCTSKATMITGB3ITGA2B | |
| SCHEMBL13456955 | 0.80 | CTSS (0.49) | CTSSCTSKATMCACNA1BAAK1 | |
| SCHEMBL15304870 | 0.80 | CA1 (0.37) | CTSSCTSKATMAAK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC | 2009-12-10 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | CTSS 1766/4885CTSK 1842/4885ATM 1110/4885 |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | KIF5B, KIF2C, PLK1 | CTSS 1713/4885CTSK 1684/4885ATM 1054/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CTSS 1766/4885CTSK 1842/4885ATM 1110/4885 |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | CTSS 1766/4885CTSK 1842/4885ATM 1110/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CTSS 1766/4885CTSK 1842/4885ATM 1110/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CTSS 1766/4885CTSK 1842/4885ATM 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.